Skip to main content

Inflammatory Bowel Disease clinical trials at UC Davis

5 research studies open to eligible people

Showing trials for
  • A Study of Experimental Therapy With Nivolumab For Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease

    open to eligible people ages 18 years and up

    The purpose of this study is to explore the safety, tolerability and activity of Nivolumab, a PD-1 inhibitor, in cohorts of patients with autoimmune disease. Two cohorts of patients will be enrolled, based on autoimmune disease type. Patients will be screened within 28 days prior to the start of dosing. Eligible patients will be enrolled in either of the two cohorts. Patients will receive treatment every two weeks, in an outpatient setting. One cycle is a 28-day period, with Nivolumab given on days 1 and 15 of a 28-day cycle. Subjects will be permitted to continue treatment beyond initial RECIST 1.1.

    Portland, Oregon and other locations

  • An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

    open to eligible people ages 12-75

    This is a Phase 3, open-label, multicenter extension study to evaluate safety and efficacy of ozanimod in subjects with moderately to severely active Crohn's Disease.

    Sacramento, California and other locations

  • An Observational Study: 5-year Long-Term Study of Patients Undergoing Therapy for Inflammatory Bowel Disease

    “Researchers are collecting information on patients with inflammatory bowel disease (IBD). Help us learn how to better treat and manage it!”

    open to eligible people ages 2 years and up

    TARGET-IBD is a 5-year, longitudinal, observational study of adult and pediatric patients (age 2 and above) being managed for Inflammatory Bowel Disease (IBD) in usual clinical practice. TARGET-IBD will create a research registry of patients with IBD within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.

    Sacramento, California and other locations

  • Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

    open to eligible people ages 12-75

    This is a Phase 3, randomized, double-blind, placebo-controlled study to explore the effect of oral ozanimod as an induction treatment for subjects with moderately to severely active Crohn's Disease.

    Mather, California and other locations

  • Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

    open to eligible people ages 12-75

    This is a Phase 3, randomized, double-blind, placebo-controlled study to explore the effect of oral ozanimod as an induction treatment for subjects with moderately to severely active Crohn's Disease.

    Sacramento, California and other locations

Last updated: